AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22361397 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents
Number of subjects: 428
Study 22361397 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents
Number of subjects: 428
Study 22361397 — intervention group
Group type: EXPERIMENTAL
Intervention: Both stent types
Number of subjects: 428
Study 19731193 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (n=10)
Number of subjects: 20
Study 19731193 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (n=10)
Number of subjects: 20
Study 18695095 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard automated perimetry for visual field progression
Number of subjects: 258
Study 15870721 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg) administered in the community setting
Number of subjects: 101
Study 15870721 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid (4 mg) administered in the hospital setting
Number of subjects: 101
Study 12832430 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-down tilt
Number of subjects: 10
Study 11100343 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin 250 mcg i.v. bolus followed by continuous i.v. infusion at a rate of 6 mg/d for 72 h
Number of subjects: 48
Study 11100343 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg/d by continuous i.v. infusion for 72 h
Number of subjects: 48
Study 9581001 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 1726
Study 9581001 — intervention group
Group type: EXPERIMENTAL
Intervention: Twelve-Step Facilitation Therapy (TSF)
Number of subjects: 1726
Study 9581001 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 1726
Study 8379502 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil
Number of subjects: 6
Study 8379502 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil
Number of subjects: 6
Study 3529884 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac alone
Number of subjects: 36
Study 3529884 — intervention group
Group type: COMPARATOR
Intervention: Aspirin + Diclofenac
Number of subjects: 36
Study 3529884 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 36
Study 29573375 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with buccal intrapapillary infiltration
Number of subjects: 98
Study 29573375 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with inferior dental nerve block and long buccal infiltration
Number of subjects: 98
Study 29573375 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (4% articaine and 2% lidocaine)
Number of subjects: 98
Study 27852621 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised physiotherapy
Number of subjects: 503
Study 27852621 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 503
Study 24404799 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily preventive asthma medication prescribed (current prescription)
Number of subjects: 310
Study 24404799 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-reported complete concordance
Number of subjects: 310
Study 24404799 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom severity (measured by symptom-free days)
Number of subjects: 310
Study 24404799 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma-related hospitalization in the prior year
Number of subjects: 310
Study 23957340 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus HN001 (6 × 10(9) cfu/day)
Number of subjects: 0
Study 23957340 — intervention group
Group type: COMPARATOR
Intervention: Bifidobacterium animalis subsp lactis HN019 (9 × 10(9) cfu/day)
Number of subjects: 0
Study 20682572 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 71
Study 20682572 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 71
Study 20682572 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with sedation
Number of subjects: 71
Study 20682572 — intervention group
Group type: COMPARATOR
Intervention: Recovery room after General anaesthesia
Number of subjects: 71
Study 20682572 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery room after Spinal anaesthesia
Number of subjects: 71
Study 20682572 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery room after Spinal anaesthesia with sedation
Number of subjects: 71
Study 19067498 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (decreased copayments for simvastatin)
Number of subjects: 13319
Study 19067498 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard copayments for non-simvastatin statins)
Number of subjects: 13319
Study 19067498 — intervention group
Group type: EXPERIMENTAL
Intervention: Elasticity of demand for statins with copayment reduction of $0 to $5
Number of subjects: 13319
Study 19067498 — intervention group
Group type: EXPERIMENTAL
Intervention: Elasticity of demand for statins with copayment reduction of >$15
Number of subjects: 13319
Study 16548349 — intervention group
Group type: EXPERIMENTAL
Intervention: Wuling pill (WLP) plus conventional therapy
Number of subjects: 90
Study 12963608 — intervention group
Group type: COMPARATOR
Intervention: Verteporfin therapy
Number of subjects: 0
Study 12963608 — intervention group
Group type: COMPARATOR
Intervention: Fluorescein angiography
Number of subjects: 0
Study 11007214 — intervention group
Group type: EXPERIMENTAL
Intervention: PDT (Photodynamic Therapy)
Number of subjects: 60
Study 11007214 — intervention group
Group type: COMPARATOR
Intervention: PDT alone
Number of subjects: 60
Study 11007214 — intervention group
Group type: EXPERIMENTAL
Intervention: PDT using a 7-cm balloon
Number of subjects: 60
Study 11007214 — intervention group
Group type: EXPERIMENTAL
Intervention: PDT using a 5-cm balloon
Number of subjects: 60
Study 11007214 — intervention group
Group type: EXPERIMENTAL
Intervention: PDT
Number of subjects: 60
Study 9006746 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral, twice daily on days 2-6)
Number of subjects: 640
Study 9006746 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg oral, twice daily on days 2/3 followed by placebo on days 4-6)
Number of subjects: 640
Study 9006746 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg oral, twice daily on days 2-6)
Number of subjects: 640
Study 9006746 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg oral, twice daily) plus Dexamethasone (4 mg oral, twice daily on days 2-6)
Number of subjects: 640
Study 31210529 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofogliflozin 20 mg/day
Number of subjects: 30
Study 31210529 — intervention group
Group type: COMPARATOR
Intervention: Ipragliflozin 50 mg/day
Number of subjects: 30
Study 31210529 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofogliflozin and Ipragliflozin (both added to sulfonylureas)
Number of subjects: 30
Study 29582237 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg BID (D150)
Number of subjects: 546
Study 29582237 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg BID (D110)
Number of subjects: 546
Study 29582237 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran (both doses)
Number of subjects: 546
Study 27436584 — intervention group
Group type: COMPARATOR
Intervention: C - cycling at 171 ± 6 W for 60 min (control)
Number of subjects: 4
Study 27436584 — intervention group
Group type: EXPERIMENTAL
Intervention: A - cycling at 171 ± 6 W for 60 min, with addition of intermittent arm exercise (98 ± 4 W)
Number of subjects: 4
Study 27436584 — intervention group
Group type: EXPERIMENTAL
Intervention: DS - cycling at 171 ± 6 W interspersed by 30 sec sprints (513 ± 19 W) every 10 min
Number of subjects: 4
Study 27436584 — intervention group
Group type: EXPERIMENTAL
Intervention: CS - cycling at 171 ± 6 W for 40 min followed by 20 min of six 30 sec sprints (clustered sprints)
Number of subjects: 4
Study 27436584 — intervention group
Group type: EXPERIMENTAL
Intervention: All protocols
Number of subjects: 4
Study 27436584 — intervention group
Group type: EXPERIMENTAL
Intervention: CS
Number of subjects: 4
Study 27436584 — intervention group
Group type: EXPERIMENTAL
Intervention: DS
Number of subjects: 4
Study 24725442 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg
Number of subjects: 8
Study 24725442 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg
Number of subjects: 8
Study 24725442 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 10 mg
Number of subjects: 8
Study 24725442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 22172468 — intervention group
Group type: EXPERIMENTAL
Intervention: Trehalose (TRE)
Number of subjects: 10
Study 22172468 — intervention group
Group type: EXPERIMENTAL
Intervention: Isomaltulose (IMU)
Number of subjects: 10
Study 18847418 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 0
Study 18847418 — intervention group
Group type: COMPARATOR
Intervention: Calcium compounds
Number of subjects: 0
Study 18847418 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer (in patients older than 65 years)
Number of subjects: 0
Study 18847418 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol and cinacalcet
Number of subjects: 0
Study 16944295 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 682
Study 16944295 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 682
Study 12692805 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube Feeding (TF)
Number of subjects: 34
Study 12692805 — intervention group
Group type: COMPARATOR
Intervention: Parenteral Nutrition (PN)
Number of subjects: 34
Study 10871712 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (1.5 mg/kg p.o.)
Number of subjects: 14
Study 10871712 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (1.4 mg i.v.)
Number of subjects: 14
Study 9347436 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 0.04 mg/kg
Number of subjects: 36
Study 9347436 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 0.6 mg/kg
Number of subjects: 36
Study 9347436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 8471816 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined preoperative treatment (group 1)
Number of subjects: 20
Study 8471816 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (group 2)
Number of subjects: 20
Study 3954130 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mm diameter resistor
Number of subjects: 15
Study 3954130 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreasing aperture size from 15 mm to 6 mm
Number of subjects: 15
Study 3954130 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreasing aperture size from 6 mm to 5 mm
Number of subjects: 15
Study 3954130 — intervention group
Group type: EXPERIMENTAL
Intervention: Throughout the study
Number of subjects: 15
Study 29177975 — intervention group
Group type: COMPARATOR
Intervention: Trabectedin 0.58 or 0.9 mg/m2 (Study #1004)
Number of subjects: 6
Study 29177975 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin 1.5 mg/m2 by 24-h IV infusion every 3 weeks (Study #3007)
Number of subjects: 6
Study 29177975 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 3-4 hepatotoxicity (Study #3007)
Number of subjects: 6
Study 28029926 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 LCPUFA (fish oil) 2.4 g per day
Number of subjects: 736
Study 28029926 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 736
Study 28029926 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 LCPUFA (fish oil)
Number of subjects: 736
Study 24970858 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (2,000 mg)
Number of subjects: 55
Study 24970858 — intervention group
Group type: COMPARATOR
Intervention: Control (identical soy/corn oil capsules)
Number of subjects: 55
Study 22861493 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient interviews
Number of subjects: 155
Study 22861493 — intervention group
Group type: COMPARATOR
Intervention: Medication and clinical records
Number of subjects: 155
Study 20487083 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium Abatement Program (DAP)
Number of subjects: 457
Study 20487083 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 457
Study 18318945 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin (oral, twice daily for 5 days)
Number of subjects: 458
Study 18318945 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (intramuscular, once daily for 2 days)
Number of subjects: 458
Study 16704037 — intervention group
Group type: EXPERIMENTAL
Intervention: TB treatment for 4 months under direct observation after 2 months of initial treatment
Number of subjects: 1075
Study 16704037 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors identified through Cox multivariate regression analysis
Number of subjects: 1075
Study 16704037 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of multiple independent risk factors
Number of subjects: 1075
Study 16704037 — intervention group
Group type: COMPARATOR
Intervention: Extent of disease and treatment failure/relapse
Number of subjects: 1075
Study 14995060 — intervention group
Group type: EXPERIMENTAL
Intervention: GSM mobile phone with speaker disabled and configured to transmit at full‐radiated power
Number of subjects: 10
Study 14995060 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐modified GSM mobile phone in active standby mode
Number of subjects: 10
Study 14995060 — intervention group
Group type: COMPARATOR
Intervention: Sham exposures
Number of subjects: 10
Study 10965418 — intervention group
Group type: EXPERIMENTAL
Intervention: benidipine (4 mg/day)
Number of subjects: 8
Study 10965418 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8
Study 8975685 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulations of participants' processing goals in Experiments 1 and 2
Number of subjects: 0
Study 8975685 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulations of participants' processing goals in Experiment 3
Number of subjects: 0
Study 8975685 — intervention group
Group type: EXPERIMENTAL
Intervention: ACME model simulation
Number of subjects: 0
Study 1335646 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of immune globulin (Ig) and hepatitis A vaccine
Number of subjects: 149
Study 1335646 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis A vaccine alone
Number of subjects: 149
Study 1335646 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Ig and vaccine
Number of subjects: 149
Study 6205489 — intervention group
Group type: EXPERIMENTAL
Intervention: 2SHT/10HT
Number of subjects: 201
Study 6205489 — intervention group
Group type: COMPARATOR
Intervention: 2SHRZ/10HT
Number of subjects: 201
Study 28474341 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg, n = 40
Number of subjects: 80
Study 28474341 — intervention group
Group type: COMPARATOR
Intervention: Placebo, n = 40
Number of subjects: 80
Study 27920484 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy (FS) screening
Number of subjects: 14294
Study 27920484 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal immunochemical test (FIT) screening
Number of subjects: 14294
Study 27920484 — intervention group
Group type: COMPARATOR
Intervention: Control group (individuals not invited to screening)
Number of subjects: 14294
Study 25335434 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetonide (IVTA)
Number of subjects: 33
Study 23951270 — intervention group
Group type: EXPERIMENTAL
Intervention: SHARP-at work intervention (2-day training in problem solving intervention)
Number of subjects: 0
Study 23951270 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 0
Study 20640584 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive nerve blocks with lidocain, corticosteroids and hyaluronic acid
Number of subjects: 0
Study 20640584 — intervention group
Group type: COMPARATOR
Intervention: Tailored surgical neurectomy
Number of subjects: 0
Study 18574679 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention (physician advice, in-person counseling with nicotine replacement therapy, 5 telephone calls)
Number of subjects: 464
Study 18574679 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention (physician advice and self-help manual)
Number of subjects: 464
Study 17043424 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (intravenous cefotaxime 2 g q 8 hr for 7 days)
Number of subjects: 120
Study 17043424 — intervention group
Group type: COMPARATOR
Intervention: On-demand antibiotics (same antibiotics only when infection became evident)
Number of subjects: 120
Study 14981967 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematopoietic growth factor-mobilized donor progenitor cells from peripheral blood
Number of subjects: 0
Study 14981967 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative conditioning regimens prior to SCT
Number of subjects: 0
Study 11115306 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventolin HFA
Number of subjects: 135
Study 11115306 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventolin CFC
Number of subjects: 135
Study 11115306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 7494588 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy in patients with preinfarction angina
Number of subjects: 23
Study 7494588 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic therapy in patients without preinfarction angina
Number of subjects: 23
Study 1387927 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous dose of ondansetron (8-32 mg)
Number of subjects: 3
Study 1387927 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 8 mg i.v. dose of ondansetron
Number of subjects: 3
Study 1387927 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 32 mg i.v. dose of ondansetron
Number of subjects: 3
Study 1387927 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron dosing regimen (8-32 mg i.v. followed by 8 mg orally twice daily)
Number of subjects: 3
Study 3993321 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 20 mg intravenously given at least 90 min before premedication
Number of subjects: 57
Study 3993321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 31189511 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide (1.5 mg weekly subcutaneous injection)
Number of subjects: 9901
Study 31189511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9901
Study 31189511 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Number of subjects: 9901
Study 28676085 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of NeuroEPO every 8 hours for 4 days (Group A)
Number of subjects: 25
Study 28676085 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg of NeuroEPO every 8 hours for 4 days (Group B)
Number of subjects: 25
Study 25584931 — intervention group
Group type: EXPERIMENTAL
Intervention: IR/ER HB/APAP 45/1950 mg (intact)
Number of subjects: 52
Study 25584931 — intervention group
Group type: EXPERIMENTAL
Intervention: IR/ER HB/APAP 22.5/975 mg (intact)
Number of subjects: 52
Study 25584931 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed IR/ER HB/APAP 45/1950 mg
Number of subjects: 52
Study 25584931 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact IR/ER HB/APAP
Number of subjects: 52
Study 23461723 — intervention group
Group type: EXPERIMENTAL
Intervention: NRP training
Number of subjects: 49
Study 23461723 — intervention group
Group type: COMPARATOR
Intervention: No NRP training
Number of subjects: 49
Study 21813293 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 50 mg (titrated to 100 mg) three times daily
Number of subjects: 40
Study 21813293 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide 2.5 mg (titrated to 5.0 mg) three times daily
Number of subjects: 40
Study 19359034 — intervention group
Group type: EXPERIMENTAL
Intervention: Encouragement to enroll in a health-insurance programme and upgraded medical facilities.
Number of subjects: 32515
Study 16682542 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy (TT) - 200 mg/mL of testosterone enanthate every 2 weeks for 8 weeks
Number of subjects: 30
Study 16682542 — intervention group
Group type: COMPARATOR
Intervention: Placebo - isotonic sodium chloride solution injections
Number of subjects: 30
Study 16682542 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term open-label TT
Number of subjects: 30
Study 16682542 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy (TT)
Number of subjects: 30
Study 16682542 — intervention group
Group type: EXPERIMENTAL
Intervention: TT group
Number of subjects: 30
Study 14707586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 564
Study 11369986 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified fluid gelatin (1000 ml)
Number of subjects: 34
Study 11369986 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution (1000 ml)
Number of subjects: 34
Study 9160527 — intervention group
Group type: EXPERIMENTAL
Intervention: Single booster dose of rabies vaccine
Number of subjects: 44
Study 9160527 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabies vaccine (HDCV)
Number of subjects: 44
Study 9160527 — intervention group
Group type: COMPARATOR
Intervention: Rabies vaccine (PCECV, PDEV, PVRV)
Number of subjects: 44
Study 9160527 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabies neutralizing antibody
Number of subjects: 44
Study 7965290 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthomet screws
Number of subjects: 25
Study 7965290 — intervention group
Group type: EXPERIMENTAL
Intervention: Ace screws
Number of subjects: 25
Study 3117982 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 51
Study 3117982 — intervention group
Group type: COMPARATOR
Intervention: Enteral nutrition (EN)
Number of subjects: 51
Study 29320378 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 5
Study 29320378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 27146963 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 8.75 mg lozenge
Number of subjects: 204